Oral GLP-1 Pills List: Every FDA-Approved GLP-1 Tablet in 2026

As of mid-2026, there are three FDA-approved oral GLP-1 receptor agonist pills on the market: Foundayo (orforglipron), Rybelsus (oral semaglutide), and the Wegovy pill (a separate, higher-dose oral semaglutide product). They aren’t interchangeable — each has its own approved use, dosing pattern, and administration rules. Here’s what’s actually available, what each one is approved for, and how they differ.

What oral GLP-1 pills are FDA-approved right now?

Pill	Active ingredient	Approved for	Food/water rules
Foundayo	Orforglipron (small molecule)	Chronic weight management	None — with or without food, no water restriction
Rybelsus	Semaglutide (peptide), 3/7/14 mg	Type 2 diabetes (blood sugar control)	Empty stomach, ≤4 oz water, ≥30 min before food/drink/other oral meds
Wegovy pill	Semaglutide (peptide), 25 mg	Chronic weight management	Same empty-stomach rule as Rybelsus (oral semaglutide)

Two other GLP-1-class medications are widely known but are not oral — Ozempic and Mounjaro/Zepbound are subcutaneous injections, not pills. They’re included here only for contrast, not because they belong on an oral-pills list.

Foundayo (orforglipron): the only non-peptide oral GLP-1

Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist made by Eli Lilly. Unlike every other GLP-1 medication on the market, it’s a small molecule, not a peptide — which is the underlying reason it doesn’t need the strict administration rules that oral peptide drugs do. Per its FDA-approved label on DailyMed, orforglipron is taken once daily, with or without food, with no water restriction, and is approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity.

If you’re deciding between orforglipron and semaglutide’s oral form, Orforglipron vs Rybelsus walks through the mechanism and administration differences in more depth. For a step-by-step look at dosing and titration, see Foundayo (Orforglipron): A Simple Guide.

What is Rybelsus approved for?

Rybelsus is the original oral GLP-1 pill, approved years before either of the newer options above. It’s oral semaglutide — a peptide, the same active ingredient as the injectable Ozempic — available in 3 mg, 7 mg, and 14 mg tablets. Per MedlinePlus, Rybelsus is approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It is not approved for chronic weight management; that’s a separate product (below).

Because it’s a peptide, Rybelsus needs specific conditions to absorb properly: taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before the day’s first food, drink, or other oral medications. Miss that window and absorption can be affected. Our How to Take Rybelsus guide covers the routine in detail.

The Wegovy pill: a separate oral semaglutide for weight management

This is the newest entry and a common source of confusion, since it’s easy to assume “oral semaglutide” only means Rybelsus. It doesn’t. Novo Nordisk’s Wegovy pill is a higher-dose (25 mg), once-daily oral semaglutide tablet approved separately from Rybelsus, specifically for chronic weight management — not for diabetes. It follows the same empty-stomach, limited-water administration pattern as Rybelsus, because it’s the same peptide delivery technology at a different dose for a different indication.

The practical takeaway: if your goal is glycemic control for type 2 diabetes, Rybelsus is the approved oral semaglutide option. If your goal is chronic weight management and you want an oral (not injectable) option, the Wegovy pill and Foundayo are both approved for that — but they differ in molecule type and administration rules, as shown in the table above.

What about oral tirzepatide?

There isn’t one. Tirzepatide — the dual GIP/GLP-1 medication sold as Mounjaro (type 2 diabetes) and Zepbound (weight management) — is, per MedlinePlus, only available as a subcutaneous injection. If you’re weighing an oral option against tirzepatide’s injectable one, Orforglipron vs Tirzepatide covers that comparison without inventing a head-to-head efficacy number neither drug has a published trial for.

Oral vs. injectable: the broader tradeoff

Not sure whether an oral pill or an injection fits your situation better in the first place? That’s a wider question than which brand to pick — our GLP-1 Pill vs Injection guide covers the general tradeoffs (administration, storage, needle aversion, and more) across the whole drug class, not just the oral options listed here.

This list will change — verify before you act

New GLP-1 candidates, including other oral options, are in various stages of clinical development industry-wide, and not every candidate that starts a trial reaches approval — some have been discontinued along the way. This article reflects only medications with current FDA approval as of the date above; it isn’t a preview of what might be approved later; and it isn’t a recommendation for any specific drug. Whether an oral GLP-1 is appropriate for you, and which one, is a decision for you and your prescriber, based on your diagnosis, health history, and the actual approved indication for each product.

Bottom line

“Oral GLP-1 pill” isn’t one product — it’s currently three approved medications with different molecules, different approved uses, and different administration rules: Foundayo (orforglipron) for weight management with no food/water restrictions, Rybelsus (oral semaglutide) for type 2 diabetes with strict empty-stomach dosing, and the Wegovy pill (higher-dose oral semaglutide) for weight management with that same empty-stomach requirement. Match the drug to the approved use, not the other way around, and confirm current details with your prescriber or pharmacist before starting anything.